Soumen K Manna1, Naoki Tanaka1, Kristopher W Krausz1, Majda Haznadar2, Xiang Xue3, Tsutomu Matsubara1, Elise D Bowman2, Eric R Fearon4, Curtis C Harris2, Yatrik M Shah3, Frank J Gonzalez5. 1. Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 2. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 3. Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan. 4. Departments of Internal Medicine, Pathology and Human Genetics, University of Michigan, Ann Arbor, Michigan. 5. Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. Electronic address: gonzalef@mail.nih.gov.
Abstract
BACKGROUND & AIMS: There are no robust noninvasive methods for colorectal cancer screening and diagnosis. Metabolomic and gene expression analyses of urine and tissue samples from mice and humans were used to identify markers of colorectal carcinogenesis. METHODS: Mass spectrometry-based metabolomic analysis of urine and tissues from wild-type C57BL/6J and Apc(Min/+) mice, as well as from mice with azoxymethane-induced tumors, was employed in tandem with gene expression analysis. Metabolic profiling was also performed on colon tumor and adjacent nontumor tissues from 39 patients. The effects of β-catenin activity on metabolic profiles were assessed in mice with colon-specific disruption of Apc. RESULTS: Thirteen markers were found in urine associated with development of colorectal tumors in Apc(Min/+) mice. Metabolites related to polyamine metabolism, nucleic acid metabolism, and methylation, identified tumor-bearing mice with 100% accuracy, and also accurately identified mice with polyps. Changes in gene expression in tumor samples from mice revealed that derangement of metabolites were a reflection of coordinate metabolic reprogramming in tumor tissue. Similar changes in urinary metabolites were observed in mice with azoxymethane-induced tumors and in mice with colon-specific activation of β-catenin. The metabolic alterations indicated by markers in urine, therefore, appear to occur during early stages of tumorigenesis, when cancer cells are proliferating. In tissues from patients, tumors had stage-dependent increases in 17 metabolites associated with the same metabolic pathways identified in mice. Ten metabolites that were increased in tumor tissues, compared with nontumor tissues (proline, threonine, glutamic acid, arginine, N1-acetylspermidine, xanthine, uracil, betaine, symmetric dimethylarginine, and asymmetric-dimethylarginine), were also increased in urine from tumor-bearing mice. CONCLUSIONS: Gene expression and metabolomic profiles of urine and tissue samples from mice with colorectal tumors and of colorectal tumor samples from patients revealed pathways associated with derangement of specific metabolic pathways that are indicative of early-stage tumor development. These urine and tissue markers might be used in early detection of colorectal cancer.
BACKGROUND & AIMS: There are no robust noninvasive methods for colorectal cancer screening and diagnosis. Metabolomic and gene expression analyses of urine and tissue samples from mice and humans were used to identify markers of colorectal carcinogenesis. METHODS: Mass spectrometry-based metabolomic analysis of urine and tissues from wild-type C57BL/6J and Apc(Min/+) mice, as well as from mice with azoxymethane-induced tumors, was employed in tandem with gene expression analysis. Metabolic profiling was also performed on colon tumor and adjacent nontumor tissues from 39 patients. The effects of β-catenin activity on metabolic profiles were assessed in mice with colon-specific disruption of Apc. RESULTS: Thirteen markers were found in urine associated with development of colorectal tumors in Apc(Min/+) mice. Metabolites related to polyamine metabolism, nucleic acid metabolism, and methylation, identified tumor-bearing mice with 100% accuracy, and also accurately identified mice with polyps. Changes in gene expression in tumor samples from mice revealed that derangement of metabolites were a reflection of coordinate metabolic reprogramming in tumor tissue. Similar changes in urinary metabolites were observed in mice with azoxymethane-induced tumors and in mice with colon-specific activation of β-catenin. The metabolic alterations indicated by markers in urine, therefore, appear to occur during early stages of tumorigenesis, when cancer cells are proliferating. In tissues from patients, tumors had stage-dependent increases in 17 metabolites associated with the same metabolic pathways identified in mice. Ten metabolites that were increased in tumor tissues, compared with nontumor tissues (proline, threonine, glutamic acid, arginine, N1-acetylspermidine, xanthine, uracil, betaine, symmetric dimethylarginine, and asymmetric-dimethylarginine), were also increased in urine from tumor-bearing mice. CONCLUSIONS: Gene expression and metabolomic profiles of urine and tissue samples from mice with colorectal tumors and of colorectal tumor samples from patients revealed pathways associated with derangement of specific metabolic pathways that are indicative of early-stage tumor development. These urine and tissue markers might be used in early detection of colorectal cancer.
Authors: David R Wise; Ralph J DeBerardinis; Anthony Mancuso; Nabil Sayed; Xiao-Yong Zhang; Harla K Pfeiffer; Ilana Nissim; Evgueni Daikhin; Marc Yudkoff; Steven B McMahon; Craig B Thompson Journal: Proc Natl Acad Sci U S A Date: 2008-11-24 Impact factor: 11.205
Authors: Takao Hinoi; Aytekin Akyol; Brian K Theisen; David O Ferguson; Joel K Greenson; Bart O Williams; Kathleen R Cho; Eric R Fearon Journal: Cancer Res Date: 2007-10-15 Impact factor: 12.701
Authors: M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry Journal: Cell Metab Date: 2019-07-25 Impact factor: 27.287
Authors: Pan Pan; Chad W Skaer; Hsin-Tzu Wang; Michael A Kreiser; Steven M Stirdivant; Kiyoko Oshima; Yi-Wen Huang; Matthew R Young; Li-Shu Wang Journal: Nutr Cancer Date: 2017-01-17 Impact factor: 2.900
Authors: Pan Pan; Chad W Skaer; Steven M Stirdivant; Matthew R Young; Gary D Stoner; John F Lechner; Yi-Wen Huang; Li-Shu Wang Journal: Cancer Prev Res (Phila) Date: 2015-06-08
Authors: Nicholas J W Rattray; Georgia Charkoftaki; Zahra Rattray; James E Hansen; Vasilis Vasiliou; Caroline H Johnson Journal: Curr Pharmacol Rep Date: 2017-04-07
Authors: Pan Pan; Chad W Skaer; Hsin-Tzu Wang; Steven M Stirdivant; Matthew R Young; Kiyoko Oshima; Gary D Stoner; John F Lechner; Yi-Wen Huang; Li-Shu Wang Journal: Carcinogenesis Date: 2015-08-05 Impact factor: 4.944
Authors: Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale Journal: CA Cancer J Clin Date: 2021-05-13 Impact factor: 286.130